RaQualia Pharma (TSE:4579) Total Liabilities: 円3,305 Mil (As of Mar. 2026)

What is RaQualia Pharma Total Liabilities?

RaQualia Pharma TSE:4579 -2.70% 56 Total Liabilities is 円3,305 Mil as of Mar. 2026. GuruFocus rates TSE:4579 with a GF Score™ of 56/100 and a GF Value™ of 円961.52 (Significantly Undervalued). The stock has 3 warning signs investors should review.

RaQualia Pharma's Total Liabilities for the quarter that ended in Mar. 2026 was 円3,305 Mil.

RaQualia Pharma's quarterly Total Liabilities declined from Jun. 2025 (円3,649.21 Mil) to Dec. 2025 (円3,617.93 Mil) and declined from Dec. 2025 (円3,617.93 Mil) to Mar. 2026 (円3,304.75 Mil).

RaQualia Pharma's annual Total Liabilities increased from Dec. 2023 (円751.53 Mil) to Dec. 2024 (円4,084.97 Mil) but then declined from Dec. 2024 (円4,084.97 Mil) to Dec. 2025 (円3,617.93 Mil).

RaQualia Pharma Total Liabilities Related Terms

RaQualia Pharma Total Liabilities Historical Data

* Premium members only.

The historical data trend for RaQualia Pharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RaQualia Pharma Total Liabilities Chart

RaQualia Pharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Liabilities

Get a 7-Day Free Trial

446.20

760.67

751.53

4,084.97

3,617.93

RaQualia Pharma Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Dec24	Mar25	Jun25	Dec25	Mar26
Total Liabilities	Get a 7-Day Free Trial															4,084.97	4,010.61	3,649.21	3,617.93	3,304.75

56GF Score

RaQualia Pharma Inc TSE:4579

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

RaQualia Pharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

RaQualia Pharma's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1275.013	+	(2310.53	+	14.724
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	17.664	+	0)
	=	3,618

Total Liabilities	=	Total Assets (A: Dec. 2025 )	-	Total Equity (A: Dec. 2025 )
	=	10514.193	-	6896.262
	=	3,618

RaQualia Pharma's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1052.467	+	(2190.599	+	14.751
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	46.928	+	0)
	=	3,305

Total Liabilities	=	Total Assets (Q: Mar. 2026 )	-	Total Equity (Q: Mar. 2026 )
	=	11391.445	-	8086.7
	=	3,305

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of 円3,305 Mil mean?

RaQualia Pharma (TSE:4579) has a Total Liabilities of 円3,305 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for RaQualia Pharma and its competitors.

Is RaQualia Pharma's Total Liabilities too high?

RaQualia Pharma's current Total Liabilities is 円3,305 Mil. Overall, RaQualia Pharma has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does RaQualia Pharma's Total Liabilities compare to VRTX and REGN?

RaQualia Pharma's Total Liabilities of 円3,305 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Biotechnology company?

A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for RaQualia Pharma and its competitors. RaQualia Pharma's current Total Liabilities is 円3,305 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is RaQualia Pharma stock overvalued right now?

Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Undervalued. The stock's GF Value™ is 円961.52, compared to a current price of 円468.00 — trading 51.3% below its estimated fair value. The current Total Liabilities is 円3,305 Mil. RaQualia Pharma's overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Total Liabilities is 円3,305 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RaQualia Pharma (TSE:4579) Overvalued in 2026?

Based on GuruFocus' analysis, RaQualia Pharma stock appears to be undervalued. The current stock price of 円468.00 is trading 51.3% below its estimated GF Value™ of 円961.52. GuruFocus considers RaQualia Pharma to be Significantly Undervalued.

Key valuation signals for TSE:4579:

Total Liabilities: 円3,305 Mil
GF Value™: 円961.52 vs. price of 円468.00 (51.3% below fair value)
GF Score™: 56/100 with 3 warning signs

No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RaQualia Pharma Business Description

Industry Healthcare Biotechnology

Comparable Companies TSE:4978 TSE:4575 TSE:4888 TSE:4570 TSE:4896 TSE:4571 TSE:4596 TSE:7776 TSE:4564 TSE:7096 VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 1-21-19 Meieki Minami, Nakamura-ku, Nagoya, JPN, 470-2341

Website https://www.raqualia.co.jp

RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.

56GF Score

Get the complete analysis for TSE:4579

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円468.00

Price

円961.52

GF Value

View TSE:4579 Analysis

See Total Liabilities data for all stocks →